SurasakPhuphanichMDFAAN

PubMed

• 33 citations
  A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma.
  Jethro Hu, Oluwaseun Adeola Omofoye, Jeremy Rudnick, Sungjin Kim, Mourad Tighiouart, Surasak Phuphanich, Hongqiang Wang, Mia Mazer, Toni Ganaway, Ray M Chu, Chirag G. ...> ;Clinical Cancer Research. 2021 Dec 3
• Correction to: Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling.
  Christopher Dardis, David Donner, Nader Sanai, Joanne Xiu, Sandeep Mittal, Sharon K. Michelhaugh, Manjari Pandey, Santosh Kesari, Amy B. Heimberger, Zoran Gatalica, Mi...> ;BMC Neurology. 2021 Aug 14
• 9 citations
  Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling.
  Christopher Dardis, David Donner, Nader Sanai, Joanne Xiu, Sandeep Mittal, Sharon K. Michelhaugh, Manjari Pandey, Santosh Kesari, Amy B. Heimberger, Zoran Gatalica, Mi...> ;BMC Neurology. 2021 Jun 23
• 684 citations
  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial
  David A. Reardon, Alba A. Brandes, Antonio Omuro, Paul Mulholland, Michael Lim, Antje Wick, Joachim M. Baehring, Manmeet Ahluwalia, Patrick Roth, Oliver Bähr, Surasak ...> ;JAMA Oncology. 2020 Jul 1
• 26 citations
  A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant gl...
  Jeremy Rudnick, J. Manuel Sarmiento, Benjamin R. Uy, Miriam A Nuno, Christopher J. Wheeler, Mia Mazer, Hongqiang Wang, Jethro Hu, Ray M Chu, Surasak Phuphanich, Keith ...> ;Journal of Clinical Neuroscience. 2020 Apr 1
• 24 citations
  Primary CNS lymphoma commonly expresses immune response biomarkers.
  Alexander Ou, Ashley Sumrall, Surasak Phuphanich, David Spetzler, Zoran Gatalica, Joanne Xiu, Sharon K. Michelhaugh, Andrew Brenner, Manjari Pandey, Santosh Kesari, W....> ;Neuro-Oncology Advances. 2020 Jan 1
• 135 citations
  A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.
  Patrick Y. Wen, David A. Reardon, Terri S. Armstrong, Surasak Phuphanich, Robert Aiken, Joseph Landolfi, William T. Curry, Jay-Jiguang Zhu, Michael Glantz, David M. Pe...> ;Clinical Cancer Research. 2019 Oct 1
• 162 citations
  The current state of molecular testing in the treatment of patients with solid tumors, 2019
  Wafik S. El-Deiry, Richard M. Goldberg, Heinz-Josef Lenz, Anthony F. Shields, Geoffrey T. Gibney, Antoinette R. Tan, Jubilee Brown, Burton L. Eisenberg, Elisabeth I. H...> ;CA. 2019 Jul 1
• 3 citations
  Post-irradiation lumbosacral radiculopathy associated with multiple cavernous malformations of the cauda equina: Case report and review of the literature.
  Doniel Drazin, Ari D Kappel, Stefan Withrow, Tiffany G. Perry, Ray M Chu, Surasak Phuphanich> ;Surgical Neurology International. 2017 Feb 20
• 15 citations
  Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma
  Surasak Phuphanich, Jeffrey Raizer, Marc C. Chamberlain, Paola Canelos, Rajesh Narwal, Shengyan Hong, Robert Miday, Minal Nade, Kevin Laubscher> ;Journal of Neuro-Oncology. 2017 Jan 1
• Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine.
  Doniel Drazin, Lutfi Al-Khouja, Ashish Patel, Jethro Hu, Surasak Phuphanich> ;Cureus. 2016 Jan 16
• 50 citations
  A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients
  Jeffrey Raizer, Pierre Giglio, Jethro Hu, Morris D. Groves, Ryan Merrell, Charles A. Conrad, Surasak Phuphanich, Vinay K. Puduvalli, Monica Loghin, Nina Paleologos, Yi...> ;Journal of Neuro-Oncology. 2016 Jan 1
• 15 citations
  Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
  Andrew D Norden, Keith L Ligon, Samantha N Hammond, Alona Muzikansky, David A Reardon, Thomas J Kaley, Tracy T Batchelor, Scott R Plotkin, Jeffrey J Raizer, Eric T Won...> ;Neurology. 2015 Jan 20
• 122 citations
  Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma
  David A. Reardon, Louis B. Nabors, Warren P. Mason, James Perry, William R. Shapiro, Petr Kavan, David Mathieu, Surasak Phuphanich, Agnieszka Cseh, Yali Fu, Julie Cong...> ;Neuro-Oncology. 2014 Aug 19
• 43 citations
  A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)
  Marc C. Chamberlain, Sean Grimm, Surasak Phuphanich, Lawrence Recht, Jay-Jiguang Zhu, Lyndon Kim, Steve Rosenfeld, Camilo E. Fadul> ;Journal of Neuro-Oncology. 2014 Apr 17
• 62 citations
  NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme
  David M. Peereboom, Manmeet Ahluwalia, Xiaobu Ye, Jeffrey G. Supko, Sarah L. Hilderbrand, Surasak Phuphanich, L. Burt Nabors, Myrna R. Rosenfeld, Tom Mikkelsen, Stuart...> ;Neuro-Oncology. 2013 Apr 1
• 42 citations
  Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors
  Marlon Garzo Saria, Courtney Corle, Jethro Hu, Jeremy Rudnick, Surasak Phuphanich, Maciej M. Mrugala, Laura K. Crew, Daniela A. Bota, Beverly Fu, Ryan Y. Kim, Tiffany ...> ;Journal of Neurosurgery. 2013 Jun 1
• 263 citations
  Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
  Surasak Phuphanich, Christopher J. Wheeler, Jeremy Rudnick, Mia Mazer, HongQian Wang, Miriam A Nuno, Jaime Richardson, Xuemo Fan, Jianfei Ji, Ray M Chu, James G. Bende...> ;Cancer Immunology, Immunotherapy. 2013 Jan 1
• 10 citations
  Postpartum extracranial bilateral vertebral artery dissection mimicking subarachnoid hemorrhage.
  Doniel Drazin, Jack Rosner, Ali Shirzadi, Surasak Phuphanich> ;The Neurologist. 2012 May 1
• 32 citations
  Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
  Louis B. Nabors, Jeffrey G. Supko, Myrna R. Rosenfeld, Marc C. Chamberlain, Surasak Phuphanich, Tracy T. Batchelor, S. Desideri, Xiaobu Ye, J. Wright, Sachin K. Gujar,...> ;Neuro-Oncology. 2011 Dec 1
• Prognostic significance of new glioma marker, laminin-411, and its inhibition by targeted nanobiopolymer in vivo.
  Ljubimova JY, Inoue S, Bannykh SI, Phuphanich S, Rudnick J, Ljubimov AV, Black KL> ;J. Clin. Oncol.. 2011-05-20
• Phase II study of verubulin (MPC-6827) for the treatment of subjects with recurrent glioblastoma naïve to treatment with bevacizumab.
  Kim LJ, Chamberlain MC, Zhu J, Raizer JJ, Grimm SA, Phuphanich S, Fadul CE, Rosenfeld S, Balch AH, Pope CC, Brulotte M, Beelen AAP, Recht LD> ;J. Clin. Oncol.. 2011-05-20
• Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
  Norden AD, Hammond S, Drappatz J, Phuphanich S, Reardon DA, Wong E, Plotkin SR, Lesser GJ, Raizer JJ, Batchelor T, Quant EC, Beroukhim R, Kaley TJ, Muzikansky A, Ciamp...> ;J. Clin. Oncol.. 2011-05-20
• Glioma-associated antigens associated with prolonged survival in a phase I study of ICT-107 for patients with newly diagnosed glioblastoma.
  Phuphanich S, Wheeler CJ, Rudnick J, Mazer M, Nuno M, Fan X, Bender J, Hawkins ES, Black KL, Yu J> ;J. Clin. Oncol.. 2011-05-20
• A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma.
  Eisenstat DD, Nabors LB, Mason WP, Perry JR, Shapiro WR, Kavan P, Phuphanich S, Fu Y, Cong XJ, Shahidi M, Reardon DA> ;J. Clin. Oncol.. 2011-05-20
• Join now to see all

Journal Articles

• Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma  
  David A Reardon, Antonio Omuro, Joachim Baehring, Surasak Phuphanich, Solmaz Sahebjam, JAMA Oncology
• Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma  
  Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ..., Neurology, 1/1/2015
• A Phase II study of Bevacizumab and Erlotinib after Radiation Therapy and Temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter methylation ...  
  Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Puduvalli VK, LoghinM, Paleologos N, Yung A, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont I..., J Neurooncol, 1/1/2015
• Phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)  
  Chamberlain M, Grimm S, Recht L, Zhu J, Rosenfeld S, Fadul C, J Neurooncol, 1/1/2014
• Phase I, randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma  
  Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Cseh A, Fu Y, Cong J, Wind S, Eisenstat DD, Neuro-Oncol, 1/1/2014
• New Approaches to Brain Tumor Therapy Consortium NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurre...  
  Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Nabors LB, Rosenfeld MR, Mikkelsen T, Grossman SA, Neuro Oncol, 1/1/2013
• Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors  
  Saria MG, Corle C, Hu J, Rudnick JD, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, Wen PY, Chen CC, Carter B, Le..., J Neurosurg, 1/1/2013
• Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent gli...  
  Batchelor T, Mulholland P, Neyns B, Nabors B, Campone M, Wick A, Mason W, Mikkelsen T, J. Clin Oncol, 1/1/2013
• Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme  
  Lai A, Tran A, Phioanh L, Nghiemphu, Pope WB, Soli OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Feh..., J. Clin Oncol, 1/1/2011
• Phase I and pharmacokinetic study of COL 3 in patients with recurrent high grade gliomas  
  Rudek M New PZ, Mikkelsen T, Alavi J, Nabors L, Grossman SA, Piantadosi S, Fisher JD, J Neurooncol, 1/1/2011
• New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma  
  Nabors LB, Supko JG, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, Desideri S, Ye X, Wright J, Gujar S, Grossman SA, Neuro Oncol, 1/1/2011
• DR5 mediated controls caspase 8 cleavage and iniation of apoptosis in human glioblastomas  
  Bellail AC, Tse MC, Song, JH, Olsen JJ, Sun SY, Hao C, J. Cell. Mol Med, 1/1/2010
• A Phase I Evaluation of the Safety of Bortezomib with Biologic Proteosome 20S Activity Correlation and the Effects of Anticonvulsants in Adults with Recurrent Malignan...  
  Supko J, Carson K, Grossman S, Nabors L, Mikkelsen T, Lesser G, Rosenfeld S, Desideri S, Olson J,, J. Neurooncol, 1/1/2010
• A phase I, II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high grade gliomas  
  Peereboom D, Carson KA, Supko J, Batchelor T, Lesser G, Mikkelson T, Grossman S, J. Neurooncol, 1/1/2010
• A Phase I Evaluation of the Safety of Escalating Doses of Atrasentan in Adults with Recurrent Malignant Glioma  
  Carson K, Grossman SA, Lesser G, Olson J, Desideri S, Mikkelsen T, Fisher J, Neuro Oncol, 1/1/2008
• Phase I Clinical Trial and Pharmacokinetic Study of Karenitecin in the treatment of Recurrent Malignant Gliomas  
  Grossman SA, Supko J, Carson K, Batchelor T, Peereboom D, Nabors G, Lesser G, Desideri S, Hausheer F, Neuro Oncol, 1/1/2008
• Phase I Analysis of BCNU Impregnated Biodegradable Polymer Wafers followed by Systemic Interferon alpha2b in Adult with recurrent Glioblastoma Multiforme  
  Olson JJ, McKenzie E, Megan SM, Zhang Z, Brat D, J. Neurooncol, 1/1/2008
• Neurologic improvement after high dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell an...  
  Phuphanich S, Brock C, J. Neurooncol, 1/1/2007
• A Pharmacokinetic Study of intra CSF (Cerebrospinal fluid) Encapsulated Cytarabine (Depocyt) for the treatment of Neoplastic Meningitis in patients with Leukemia, Lymp...  
  Bernard M, Braeckman R, Chamberlain M, J. Neurooncol, 1/1/2007
• Lipid rafts and nonrafts mediate TRAIL induced apoptic and non apoptic signals in non small cell lung carcinoma cells  
  Song JH, Tse MC, Bellail A, Khuri Fadlo, Kneteman NM, Hao C, Cancer Research, 1/1/2007
• A multicentre, randomized, double blind, placebo (PB) controlled trial of Marimastat (MT) in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS) following ...  
  Levin VA, Yung WK, Forsyth P, Mastro R, Perry J, Elliott M, Baillet M, J. Neurooncol, 1/1/2006
• Treatment related myelitis in hodgkin’s lymphoma following stem cell transplant, chemotherapy and radiation: a case report and review of the literature  
  Gatcombe H, Lawson J, Crocker I, J. Neurooncol, 1/1/2006
• The Effect of Enzyme Inducing Anti-Seizure Drugs on the Pharmacokinetics and Maximum Tolerated Dose of Procarbazine Hydrochloride  
  Grossman SA, Supko J, Batchelor T, Lesser G, Mikkelsen, Alivi J, Carson K, Fisher J., Clinical Cancer Research, 1/1/2006
• Phase II trial of Copper Depletion as for the Angiosuppresive treatment of Newly Diagnosed Glioblastoma Multiforme  
  Brem S, Grossman S, Carson K, New P, Alavi J, Mikkelsen T, Priet R, Neuro Oncology, 1/1/2005
• A Phase II Study of Weekly Irinotecan in Adults with recurrent Malignant Glioma: Final Report of NABTT  
  Batchelor T, Gilbert M, Supko J, Nabors L, Grossman S, Lesser G, Mikkelsen T, Neuro Oncol, 1/1/2004
• Join now to see all

Abstracts/Posters

• A randomized, double blind, controlled phase II trial of dendritic cell (DC) vaccination with ICT107 in newly diagnosed glioblastoma (GBM) patients
  Wen P, Reardon D, Armstrong T, Aiken R, Landolfi J, Curry W, Zhu J, Glantz M, Peerboom D, Markert J, Grewal J, LaRocca R, O'Rourke D, Fink K, Kim L, Gruber M, Lesser G..., American Society of Clinical Oncology, Chicago, IL, 1/1/2014
• Nanoconjugates for inhibition of laminin 411-integrin B1 Dll4 Notch1 pathway to treat glioblastoma multiforme
  Gangalum PR, Ljubimov AV, Chesnokova A, Konda B, Ding H, Portilla-Arias J, Mamelak A, Bannykh S, Rudnick J, Hu J, Black KL, Ljubimova JY, Cancer Res, 1/1/2014
• Correlation of Survival with Tumor Antigen Expression in Patients with Newly Diagnosed Glioblastoma Receiving a Multi Epitope Pulsed Dendritic Cell Vaccine
  Wheeler C, Rudnick J, Mazer M, Nuno M, Fan X, Bender J, Hawkins E, Patil C, Black K, Yu J, American Society of Clinical Oncology, Chicago, IL, 1/3/2012
• Retrospective Analysis of Glioblastoma Patients Treated with Bevacizumab who Presented with Multifocal Disease at Diagnosis
  Hu J, Nosova K, Nuno M, Yi A, Elramsisy A, Mukherjee D, Rudnick J, Bannykh S, Yu J, Black K, Patil C., American Society of Clinical Oncology, Chicago, IL, 1/3/2012
• The final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with...
  Rudnick, J, Hu J, Luptrawan A, Wheeler C, Mazer M, Nuno M, Chu R, Black K, Yu J, American Society of Clinical Oncology, Chicago, IL, 1/3/2012
• A randomized, double blind, controlled phase IIb study of the safety and efficacy of ICT 107 in newly diagnosed patients with glioblastoma multiforme following resecti...
  Hawkins E, Aiken R, Chandler J, Fink K, Glantz M, Grewal J, Gruber M, Kesari S, Landolfi J, LaRocca R, Lesser G, Markert J, Mayer T, O'Rourke D, Peereboom, American Society of Clinical Oncology, Chicago, IL, 1/3/2012
• BTTC08 01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT prom...
  Raizer J, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Puduvalli V, Loghin M, Paleologos N., Yung A, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-L..., American Society of Clinical Oncology, Chicago, IL, 1/3/2012
• Phase II study of monthly Pasireotide LAR (SOM230C) for recurrent or progressive meningioma
  Norden D, Hammond S, Drappatz J, Phuphanich S, Reardon D, Wong E, Plotkin S, Lesser GJ, Raizer J, Batchelor EC, Quant R, Beroukhim T, Kaylee A, Muzikansky A, Ciampa L..., American Society of Clinical Oncology, Chicago, IL, 1/4/2011
• A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21out of 28 days) in the treatment of patients with recurrent glioblastoma
  Eisenstat D, Nabors L, Mason W, Perry J, Shapiro W, Kavan P, Fu Y, Cong X, Shahidi M, Reardon D., American Society of Clinical Oncology; J Clin Oncol, Chicago, IL, 1/1/2011
• Glioma associated antigens associated with prolonged survival in a phase I study of ICT 107 for patients with newly diagnosed glioblastoma
  Wheeler C, Rudnick J, Mazer M, Nuno M, Fan X, Bender J, Hawkins E, Black K, Yu J, American Society of Clinical Oncology; J Clin Oncol, Chicago, IL, 1/1/2011
• Phase 2 study of verubulin (MPC 6827) for the treatment of subjects with recurrent glioblastoma naive to treatment with bevacizumab
  Kim L, Chamberlain M, Zhu J, Raizer J, Grimm S, Fadul C, Rosenfeld S, Balch A, Pope C, Brulotte M, Beelen A, Recht L., American Society of Clinical Oncology; J Clin Oncol, Chicago, IL, 1/1/2011
• Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107)
  Rudnick J, Chu R, Mazer M, Wang H, Serrano N, Richardson J, Wheeler C, Black K, Singh M, Yu J, American Society of Clinical Oncology; Proc Am Soc Clin Oncol, Chicago, IL, 1/1/2010
• Phase I II Study of BIBW 2992 with or without daily temozolomide in the treatment of patients with recurrent malignant glioma
  Reardon DA, Thurm H, Fink K, Giglio P, Shapiro W, LaRocca R, Mikkelsen T, Portnow J, Schiff D., American Society of Clinical Oncology; Proc Am Soc Clin Oncol, Chicago, IL, 1/1/2010
• Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma mult...
  Lai A, Nghiemphu P, Green R, Spier L, Peak S, Fehrenbacher L, Kolevska T,Polikoff J, Cloughesy T., Proc Am Soc Clin Oncol, 1/1/2009
• A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for pa...
  Rudnick J, Chu R, Mazer M, Wang H, Serrano N, Francisco F, Black KL, Wheeler C, Yu, Proc Am Soc Clin Oncol, 1/1/2009
• A placebo-controlled study investigating the dexamethasone-sparing effects of corticorelin acetate in patients with primary or metastatic brain tumors and peritumoral ...
  Recht LD, Mechtler L, Hormigo A, Hines V, Milsted R, O'Connor PC, Ryan RP, Wong ET, ProcAm Soc Clin Oncol, 1/1/2009
• Phase I Study of getifinib and rapamycin in adult patients with recurrent glioblastoma multiforme (GBM).
  Chu R, Yu J, Black K., AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Proc Am Soc Clin Oncol, San Francisco, CA, 2007, 1/1/2008
• A phase I trial of sorafenib (BAY 43 9006) for patients with recurrent or progressive malignant glioma (NABTT 0401)
  Nabors L, Rosenfeld M, Chamberlain M, Batchelor, Supko J, Desideri S, Xiaobu Y, Wright J, Grossman S., Proc Am Soc Clin Oncol, 1/1/2007
• New Approaches to Brain Tumor Therapy (NABTT) CNSConsortium. A phase I study of SDX 102 for the treatment of patients with MTAP-deficient recurrent malignant gliomas
  Chamberlain M, Mikkelsen T, Ye X, Grossman SA, Batchelor T, Lesser G, Fisher J, Desideri S, Proc Am Soc Clin Oncol, 1/1/2007
• Phase I Analysis of Systemic Interferon alpha Utilized with Gliadel in subjects with recurrent Glioblastoma Multiforme
  McKenzie E, Greiner K, Shire K, Olson JJ, Neurology, 1/1/2006
• Phase I trial of Bortezomib in adults with recurrent malignant glioma
  Supko J, Carson K, Grossman S, Nabors L, Mikkelsen T, Lesser G, Rosenfeld M, Desideri S, Olson J., Proc Am Soc Clin Oncol, 1/1/2006
• Phase I study of Karenitecin in the treatment of recurrent malignant gliomas (MG)
  Lesser GJ, Grossman SA, Carson KA, Batchelor T, Peereboom D, Nabors LB, Supko J, Hausheer F, Proc Am Soc Clin Oncol, 1/1/2005
• NABTT 2111: A Phase I trial of BMS-247550 for patients with recurrent high-grade gliomas
  Peereboom D,Batchelor T, Lesser G, Mikkelsen T,Carson K, Desideri S, Fisher J, Grossman SA, Proc Am Soc Clin Oncol, 1/1/2005
• Intratumoral pharmacokinectics dtermined with microdialysis in a patient with glioblastoma multiforme following systemic administration of high dose methotrexate
  OlsonJJ, Supko J, McKenzie E, Grossman SA, Proc Am Soc Clin Oncol, 1/1/2005
• A Phase I Study of Col3 Administered on a continuous oral schedule in patients with Recurrent High-Grade Glioma: Results of the NABTT 9809 Clinical Trial
  New PZ, Mikkelsen T, Alavi J, Nabors L, Grossman S, Pitantidose S, Rudek M, Fisher J, American Academy of Neurology, Neurology, 1/1/2004
• Join now to see all

Lectures

• Advances in Neuro-Oncology 2015: Biomarker, Liquid Biopsy Immuno-Oncology, NovoTTF 
  Ramathibodi Hospital, Mahidol University, Bangkok, Thailand - 1/16/2015
• Targeted Therapy for Brain Cancer: Early Detection and New Biomarker 
  Mahachai Hospital Group, Samutsakhon, Thailand - 1/15/2015
• Immunotherapy for Brain cancer: Vaccine, ICT 107 Anti PD1 PD L1 Antibody 
  Houston Methodist Hospital, Houston, TX - 1/24/2014
• Immunotherapy for Brain cancer: Vaccine, PD1 PD-L1 Antibody 
  Sydney, Australia - 1/17/2014
• Immunotherapy for Brain Cancer: Vaccine ICT 107 ANTI PD 1 PP L1 ANTIBODY 
  Siriraj Hospital, Bangkok, Thailand - 1/4/2014
• Breakthrough Brain Cancer Immunotherapy: Vaccine and Anti PD 1 PD L1 
  Ramathibodi Hospital, Mahidol University, Bangkok, Thailand - 1/4/2014
• Phase I trial of a multi-epitope pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma 
  Leuven, Belgium - 1/7/2012
• Biomarker for Glioma: Prognostic or Predictive and ASCO NeuroOncology 
  Cedars Sinai Medical Center - 1/28/2011
• Update Treatment in Gliomas 
  Dusit Thani, Mahidol University, Bangkok, Thailand - 1/20/2011
• Vaccine Immunotherapy Targeting Stem Cell for Brain Cancer 
  Chaophya Hospital, Bangkok, Thailand - 1/19/2011
• A Multi-epitope pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma demonstrates correlated survival and tumor antigen expression 
  Aspen, CO - 1/2/2011
• Personalized Medicine for Brain Cancer: Vaccine Immunotherapy 
  University of California, Irvine, 2010; Dusit Thani, Mahidol University, Bangkok, Thailand - 1/1/2011
• Future Directions in Nanomedicine, BBB Modification and Vaccine Immunotherapy for Brain Cance 
  University of California, San Diego - 1/14/2010
• Personalized Medicine for Brain Cancer 
  Cedars Sinai Medical Center - 1/22/2009
• Bio-Chemotherapy 
  Ritz Carlton, Marina Delray - 1/14/2009
• Novel Bio-Chemotherapy for Brain Cancer 
  Gabon, Africa - 1/31/2008
• Pitfall in Diagnosis of Brain tumor and Treatment of Low Grade Glioma 
  Cedars Sinai Medical Center - 1/26/2008
• Emerging Molecular Targeted Therapy of Brain Cancer and Research at Cedars 
  Las Vegas - 1/11/2008
• Future Direction of Molecular Targeted Therapy for Brain Cancer 
  Cedars Sinai Medical Center - 1/10/2008
• Emerging Molecular Targeted Therapy for Brain Cancer 
  Boca Raton Community Hospital, Boca Raton, FL, 2005; Cedars Sinai Medical Center - 1/1/2008
• New Approaches to Low Grade and High Grade Glioma 
  Bangkok, Thailand - 1/1/2008
• Advances in Management of Metastatic Brain Cancer and Leptomeningeal Disease 
  Bangkok, Thailand - 1/1/2008
• Molecular Targeted Therapy for Brain Cancer 
  Bangkok, Thailand - 1/1/2008
• Emerging Molecular Targeted Therapy for Brain Cancer Research Seminar 
  San Diego; Cedars Sinai Medical Center - 1/1/2008
• Molecular Targeted Therapy of Brain Tumor 
  Columbus, GA - 1/27/2007
• Join now to see all